A Phase I Study of STK-012 Alone and with Pembrolizumab Immunotherapy in People with Solid Tumors

Full Title

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications

Purpose

The purpose of this study is to find the highest dose of the investigational drug STK-012 that can be given safely in combination with pembrolizumab immunotherapy to people with solid tumors that have spread or come back despite prior treatment. STK-012 is a modified form of a protein called interleukin-2, which is normally made by the immune system. It may help to multiply and activate tumor-killing cells of the immune system.

Pembrolizumab takes the brakes off the immune response, boosting the ability of the immune system to detect and destroy cancer cells. Researchers believe both drugs used together may be more effective against advanced solid tumors than either one alone. STK-012 is given as a subcutaneous (under the skin) injection and pembrolizumab is given intravenously (by vein).

Contact

For more information about this study and to ask about eligibility, please contact the office of Dr. Adam Schoenfeld at 646-608-4042.